Citations

Showing 10 of 107850 citations.

Supporting frontline staff in frontotemporal degeneration research
Dodge, Shana , Carter, D., Kamel, Dahlia, Lunde, Angela, Hlava, Quinn, Nelson, Kevin, Lunde, Angela , Nelson, Kevin M., Dacks, Penny A.

Mayo Clinic

Frontiers in Neurology | September 11, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fneur.2026.1906002 | PMID 42798361 Get It

Introduction Clinical Research Coordinators (CRCs) serve as the frontline staff for research participants in studies on frontotemporal degeneration (FTD), directly influencing participant experience. The training adequacy, job satisfaction, and retention of FTD CRCs have not been systematically examined. Methods The Association for Frontotemporal Degeneration (AFTD) administered an anonymous cross-sectional online survey to CRCs affiliated with research networks across the USA and Canada. Results Thirty-seven CRCs responded. Most had more than 3 years of experience, yet 62% reported encountering situations for which they felt inadequately prepared. Information on genetics, symptom management, and brain donation were identified as critical training gaps. Retention was linked to competitive pay and clear career advancement opportunities. Discussion The findings highlight a critical need for formalized, disease-specific onboarding and emotional support systems tailored to CRCs that engage with FTD patients and families. AFTD is developing a modular training curriculum to standardize CRC competency.
The Effect of Obesity on the α-Cell Response to Hyperglycemia in the Presence of Amino Acids
Man, Chiara Dalla , Vella, Adrian , Egan, Aoife M. , Mohan, Sneha , Christie, Hannah E. , Boscolo, Francesca S. , Mohan, Sneha , Boscolo, Federica , Christie, Hannah E , Egan, A M , Jensen, Michael , Nair, K Sree, Dalla Man, Chiara , Vella, Adrian , Bailey, Kent R. , Jensen, Michael D. , Nair, K. Sree

Mayo Clinic

Diabetes | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2337/db26-0502 | PMID 42726473 Get It

Hyperglycemia in prediabetes is accompanied by increased amino acid (AA) concentrations and impaired suppression of glucagon secretion by glucose. It is unknown whether an abnormal response to AA contributes or hepatic steatosis exacerbates α-cell dysfunction. Therefore, lean participants and participants with obesity (with and without hepatic steatosis) were studied on two occasions in random order using a graded glucose infusion. Saline or an AA mixture was infused. The glucagon secretion rate (GSR) was derived from peripheral glucagon concentrations, and the change in glucose required to reduce GSR by 50% (G50) was calculated for each participant. AAs were measured during the experiment. On both occasions, experimental conditions produced a progressive rise in insulin secretion and an inverse exponential suppression of glucagon. G50 did not differ between groups in response to glucose alone. AA infusion did not change G50 in lean participants. G50 increased during AA infusion in participants with obesity with and without hepatic steatosis, leading us to report these participants as a single group. The relative change in AA concentrations across study days was generally similar between groups. We conclude that despite a normal response to glucose, obesity increases α-cell responses to AA in humans. Article Highlights The aim of this study was to understand the pathogenesis of α-cell dysfunction in prediabetes. The primary hypothesis was that α-cell responsivity to glucose (reduction of the glucagon secretion rate by 50%) is impaired by amino acid (AA) infusion. A secondary hypothesis was that this abnormal response is exacerbated by hepatic steatosis. AA infusion impaired α-cell suppression in response to rising glucose in participants with obesity, but not in lean participants, despite a normal response to glucose alone. This abnormal response was unaffected by the presence or absence of hepatic steatosis. It seems likely that an abnormal α-cell response to AAs precedes an abnormal response to glucose alone.
Association Between Orbital Volume and Body Mass Index
Garcia, Maria D., Bloch, Jackson F. , Eckel, Laurence J. , Bradley, Elizabeth A., Bradley, Elizabeth A.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/iop.0000000000003288 | PMID 42727024 Get It

Purpose: Obesity is a major public health concern, and fat comprises a substantial portion of the orbital volume. We aimed to evaluate the relationship between body mass index (BMI) and orbital fat volume, and to assess whether BMI is associated with radiographic proptosis. Methods: We conducted a cross-sectional study of 99 orbits from patients who underwent orbital CT imaging between January 1 and December 31, 2018. Patients with systemic diseases affecting the orbits were excluded. When applicable, only the healthy orbit was analyzed. Subjects were evenly stratified into normal-weight, overweight, and obese groups by BMI. Using Visage Imaging Software, orbital structure volumes were measured. Orbital fat volume was calculated by subtracting extraocular muscle, globe, and optic nerve volumes from the total orbital volume. Multivariable linear regression, adjusted for age, gender, and race, assessed associations between BMI and orbital measurements. Results: Among individuals with BMI 17 to 25, total orbital volume increased by 1.20 cm 3 and orbital fat volume by 1.05 cm 3 per unit BMI. For BMI >25, both increased at a flatter slope. Obese patients had nearly double the orbital fat volume of normal-weight patients (10.7 vs. 5.4 cm 3 , p < 0.001). Radiographic proptosis trended higher in obese patients by 1.7 mm ( p = 0.114). Males had larger orbital structures and greater mean proptosis than females. Conclusions: Total orbital and fat volumes increased with BMI, particularly in the normal-to-overweight range. These findings support the need to update normative proptosis data and suggest weight loss may aid in managing mild symptomatic proptosis.
Endocrine Outcomes of Pediatric Sellar and Parasellar Lesions: A Population-Based Cohort Study
Mouallem, Rayane El, Leopold, Kaitlin, Saba, Leslie, Lteif, Aida, Mouallem, Rayane El, Leopold, Kaitlin , Saba, Leslie , Nofal, Alaa Al , Lteif, Aida

Mayo Clinic

No container title available | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10909129/v1 Get It

Abstract Purpose Sellar and parasellar lesions in children have heterogeneous clinical presentations and variable endocrine morbidity. Population-based data describing endocrine outcomes across lesion types and management strategies remain limited. Methods We conducted a retrospective, population-based cohort study of patients aged 18 years or younger who were diagnosed with sellar or parasellar lesions between 1976 and 2021 in a multicounty region. Clinical presentation, lesion characteristics, management, and endocrine outcomes were abstracted from medical records. Associations were evaluated by lesion type, lesion size (< 10 mm vs. ≥10 mm), and management approach. Results Among 104 patients, endocrine abnormalities at diagnosis differed by lesion type (p = 0.0004) and were most frequent among patients with pituitary adenomas. Endocrine dysfunction at presentation was more common with lesions ≥ 10 mm than with lesions < 10 mm (74.2% vs. 49.2%; p = 0.0217). Post-treatment endocrine abnormalities were also more common with lesions ≥ 10 mm (64.5% vs. 13.1%; p < 0.0001). Surgical treatment was associated with a higher prevalence of post-treatment endocrinopathy, although this association may reflect lesion size, diagnosis, and treatment selection. Conclusions Endocrine morbidity was common in this population-based pediatric cohort and was associated with lesion type and size. Clinically relevant endocrine abnormalities also occurred in smaller lesions, supporting endocrine evaluation regardless of lesion size and the need for longitudinal surveillance in patients with sellar and parasellar disease.
Gender Differences in Treatment Burden and Care Sustainability Among Adults Living With Diabetes
Montori, Víctor M. , Montori, Victor M , Rivadeneira, Francisco D., Rabeaa, Omar M., Shah, Brandon N., Branda, Megan E. , Brito, Juan P.

Mayo Clinic

No container title available | September 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.08.26362531 Get It

ABSTRACT Objective Women carry disproportionate shares of caregiving and other life demands that may compound the work of diabetes self-management. We sought to examine gender differences in overall and digital treatment burden and their key contributors. Research Design and Methods Cross-sectional analysis of two cohorts of adults with type 1 or type 2 diabetes attending outpatient endocrinology visits who completed the Treatment Burden Questionnaire Plus Digital (TBQ+D) (n=472). Multivariable regression estimated gender differences in overall and digital treatment burden, ability to live a normal life, and sustainability of current self- care effort, adjusting for age, diabetes type, insulin intensity, HbA1c, and cohort. Item-level analyses identified contributors to observed differences. Results Compared to men, women reported higher median overall treatment burden (33 vs 20, adjusted mean difference 10.6 points, 95% CI 5.1–16.3; p <.0001) and digital treatment burden (13 vs 7, adjusted mean difference 3.5 points, 95% CI 1.1–6.1; p =.009). They also had higher odds of not living a normal life (OR 1.77, 95% CI 1.18–2.67; p =0.006) and difficulty sustaining current self-care efforts indefinitely (OR 2.01, 95% CI 1.10–3.66; p =0.023). Digital burden differences were concentrated in annoyance, precautions, and time and effort required to use digital medicine tools, whereas contributors to differences in overall burden varied, with relationships, self-monitoring, and injections contributing most. Conclusions After adjusting for treatment intensity and other factors, women living with diabetes were twice as likely to be overwhelmed by diabetes care than men. Their greater vulnerability to treatment burden demands healthcare service redesign and individualization of plans of care that minimally disrupt patients’ and caregivers’ lives. ARTICLE HIGHLIGHTS Why did we undertake this study? Women may experience greater treatment burden across chronic conditions, reflecting competing (caregiving) demands that reduce capacity for self-management. Gender differences in diabetes, especially digital burden, remain unclear. What is the specific question we wanted to answer? Do women with diabetes experience greater overall and digital treatment burden than men? What did we find? Women reported greater overall and digital burden and more difficulty living a normal life and sustaining care than men. Differences were larger for digital annoyance, precautions, and effort, plus relationships, self-monitoring, and injections. What are the implications? Treatment burden cannot be inferred from treatment intensity alone. Diabetes care should consider whether treatment work fits within each patient’s life and can be sustained. Women with diabetes may be particularly vulnerable to becoming overwhelmed by the work of diabetes care.
Model-based motion simulation framework for deep learning-assisted motion correction in dynamic wrist CT
Zhao, Kristin D. , Treb, Kevin , Gu, Chunming , Davis, Aeden K , Huang, Shengbing, Treb, Kevin , Trentadue, Taylor P , Sadeghian, Maryam , Baffour, Francis , Trentadue, Taylor P , Leng, Shuai , Gong, Hao , Gu, Chunming , Thoreson, Andrew R. , Lachman, Nirusha , Baffour, Francis, Trentadue, Taylor P. , Kakar, Sanjeev , McCollough, Cynthia H, Leng, Shuai , Gong, Hao

Mayo Clinic

Physics in Medicine & Biology | September 11, 2026 | Volume: 71 | Issue: 18 | Pages: 185014

10.1088/1361-6560/aea684 | PMID 42727609 Get It

Abstract Objective. Four-dimensional CT (4DCT) enables visualization of dynamic wrist joint pathology but may be compromised by motion artifacts. Deep learning (DL)-assisted motion correction has the potential to enhance wrist 4DCT quality, but model development is hindered by scarce training data. To address this, we developed a model-based motion simulation framework that generated realistic 4DCT data with paired static ground truth images to demonstrate wrist motion correction using a physics-informed DL model trained with simulated data. Approach. Wrist motion was simulated by synchronizing rotational and translational movements of carpal bones and connective tissues. Elastic deformation guided by analytically-derived motion vector fields was applied to static wrist scans at neutral positions to create artifact-free images at multiple angular positions. Virtual motion-corrupted 4DCT images were produced via forward projection and reconstruction with synchronized gantry and wrist motion. Experimental data from 4DCT cadaver scans were collected to validate simulation quality. Low-intensity region score (LIRS), positivity, and entropy were used to assess simulated motion artifacts. A physics-informed motion correction network was adapted exclusively using simulated training data and subsequently deployed on simulated, real cadaveric, and in vivo 4DCT scans. LIRS and structural similarity index (SSIM) were used to evaluate motion correction quality. Wilcoxon signed-rank tests were conducted ( α = 0.05). Results. The simulation method created realistic motion artifacts compared to real scan reference ( p > 0.05). Motion artifacts were effectively mitigated across testing cases demonstrating generalizability. In simulated scans, LIRS improved from 0.55 ± 0.12–0.75 ± 0.04 and SSIM from 0.87 ± 0.08–0.95 ± 0.03 at bone regions (each p < 0.01). In experimental cadaveric scans, LIRS improved from 0.05 ± 0.01–0.31 ± 0.17 in marker regions and from 0.58 ± 0.19–0.77 ± 0.14 in bone regions (each p < 0.01). Significance. Our simulation method facilitates training DL-assisted motion correction algorithms by providing high-quality training data, effectively supporting 4DCT image quality enhancement.
Recent advancements in gynecologic cancer research: a SPORE investigators meeting report
Curtis, Marion , Benbrook, Doris M. , Kanakkanthara, Arun , Curtis, Marion , Levinson, Kimberly L. , Kannan, Nagarajan , Hannafon, Bethany N. , Kozbor, Danuta , Chandra, Vishal, Hempel, Nadine , Leslie, Kimberly Kay , Liang, Han, Powell, M. A., Rai, Rajani , Steinkamp, Mara P. , Xue, Xiang

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag319 | PMID 42745474 Get It

Abstract Global incidence and mortality rates for endometrial and cervical cancers have been steadily rising, while these rates for ovarian cancer have decreased. Although these cancers represent unique diseases and challenges, overlapping biology and responses to targeted and immunotherapies create opportunities to advance research through shared knowledge and resources. In 2025, investigators funded by National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) and other NCI-supported grants convened a hybrid meeting to identify challenges and knowledge gaps in translational research, highlight advances, define shareable resources and technologies, and foster collaboration among the Gynecologic Cancer SPORE sites, patient advocates, and NCI staff. Special sessions were arranged for presentations by Patient Advocates, Early-stage Investigators, Investigators Transitioning to Gynecologic Cancer Research. Meeting-wide workshops on Sharing Resources and Reducing Time to Activation of Clinical Trials and networking events were included. Collectively, the presentations converged on three overarching themes: (i) interception and early disease biology, (ii) development of innovative targeted and immune-based therapies, (iii) critical role of shared resources and collaborative infrastructure in accelerating translational progress. The unifying theme across disease sites was molecular advances to improve early detection/prevention and to drive therapeutic advancements. Novel findings discussed included: candidate precursor cells and mechanisms of high grade serous ovarian cancer development; therapeutic vaccines and their delivery methods for cervical dysplasia; identification of immune-targetable ovarian cancer antigens; various novel molecularly targeted drugs and immune-based agents for endometrial and ovarian cancers; and approaches to bypass drug resistance. Workshops delineated actionable strategies to further advance gynecologic cancer translational research.
Food-based enteral formulas in pediatric clinical practice: an expert opinion
O’Connor, Graeme , Diamanti, Antonella , Trovato, Chiara Maria , Romano, Claudio , Minor, Gerard J. , Letellier, Guy , Huysentruyt, Koen , Epp, Lisa , Tobberup, Randi , Durnan, Sarah , Marchand, Valerie , Epp, Lisa M , Dipasquale, Valeria , Marchand, Valerie , Gottrand, Frederic , Gottrand, Frédèric

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-16

10.1080/17474124.2026.2726787 | PMID 42720678 Get It

Performance evaluation of a large language model for medication management tasks
Henry, Kelli , Xu, Steven, Blotske, Kaitlin , Cargile, Moriah , Barreto, Erin F, Murray, Brian, Smith, Susan, Bauer, Seth R, Tilley, Adeleine , Liu, Tianming, Sohn, Sunghwan , Gao, Yanjun , Sikora, Andrea , Smith, Susan E , Murray, Brian , Frazee, Erin N. , Murray, Brian , Smith, Susan , Bauer, Seth R , Zhao, Xingmeng , Gao, Yanjun , Liu, Tianming

Mayo Clinic

American Journal of Health-System Pharmacy | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajhp/zxag282 | PMID 42717660 Get It

Abstract Purpose Large language models (LLMs) have proven performance for certain diagnostic tasks; however, limited studies have evaluated their consistency in recommending appropriate medication regimens for a given diagnosis. Medication management is a complex task that requires synthesis of drug formulation and complete order instructions for safe use. Here, the performance of GPT-4o, an LLM available with OpenAI’s ChatGPT, was tested on 3 medication management tasks. Methods GPT-4o performance was tested on 3 medication tasks: identifying available formulations for a given generic drug name, identifying drug-drug interactions (DDIs) for a given medication regimen, and preparing a medication order for a given generic drug name. For each experiment, the model’s raw text response was captured exactly as returned and evaluated using clinician evaluation in addition to standard LLM metrics, including Term Frequency-Inverse Document Frequency (TF-IDF) vectors, normalized Levenshtein similarity, and Recall-Oriented Understudy for Gisting Evaluation (ROUGE-1/ROUGE-L) F1 score between each response and its reference string. Results For the first task of drug-formulation matching, GPT-4o had 49% accuracy for generic medications being matched to all available formulations, with an average of 1.23 omissions per medication and 1.14 hallucinations per medication. For the second task of drug-drug interaction identification, the accuracy was 54.7% for identifying the DDI pair. For the third task, GPT-4o generated order sentences containing no medication or abbreviation errors in 65.8% of the cases. Conclusion Model performance for basic medication tasks was consistently poor. This evaluation highlights the need for domain-specific training through clinician-annotated datasets and a comprehensive evaluation framework for benchmarking performance.
Beyond transfusions: bleeding-related outcomes after repeat TURP
Liu, Eric, Lange, Dirk , Bhojani, Naeem, Wymer, Kevin, Forbes, Connor M. , Derigs, Marcus , Bhojani, Naeem , Forbes, Connor M.

Mayo Clinic

No container title available | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10532565/v1 Get It

Abstract Purpose We compared perioperative morbidity after repeat transurethral resection (re-TURP) versus primary TURP, focusing on transfusion and broader bleeding-related complications relevant to counseling and risk stratification. Methods We analyzed the American College of Surgeons National Surgical Quality Improvement Program (2013–2023) to identify men undergoing primary TURP (Current Procedural Terminology [CPT] 52601) or re-TURP (CPT 52630). The primary outcome was 30-day red blood cell transfusion. Secondary outcomes included a prespecified postoperative hematuria endpoint based on ICD-10 codes. Multivariable logistic regression evaluated associations with bleeding endpoints and downstream complications. Results Among 83,539 TURP procedures, 76,983 (92.2%) were primary and 6,556 (7.8%) were repeat. Re-TURP patients were older, had higher ASA class, and more often underwent urgent surgery. Transfusion occurred in 1.9% after re-TURP versus 1.5% after primary TURP; hematuria-coded events occurred in 3.5% versus 1.3%, respectively. After adjustment, re-TURP was associated with postoperative hematuria (adjusted odds ratio [aOR] 2.42, 95% CI 2.03–2.88) but not with transfusion (aOR 1.09, 95% CI 0.87–1.36). Older age, urgent/emergent status, bleeding disorder, and lower hematocrit predicted both bleeding endpoints. Re-TURP was associated with slightly lower odds of readmission (aOR 0.87; 95% CI 0.76–0.99) and was not associated with return to the operating room. Transfusion strongly predicted return to the operating room (aOR 7.21) and readmission (aOR 2.05), whereas hematuria predicted return to the operating room only (aOR 1.50). Conclusions Compared with primary TURP, re-TURP was associated with more hematuria-coded events but not higher adjusted transfusion risk, suggesting a relative shift toward lower-severity bleeding morbidity.